EFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICO
Autor(a) principal: | |
---|---|
Data de Publicação: | 1995 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://www.arquivosonline.com.br/pesquisartigos/Pdfs/1995/V64N6/64060014.pdf http://hdl.handle.net/11449/64629 |
Resumo: | Purpose. To evaluate the antihypertensive efficacy and tolerability of captopril 50 mg + hydrochlorothiazide 25 mg daily in mild to moderate primary hypertension. Methods. Out-patients (n = 471) with mild to moderate hypertension, diastolic blood pressure (DBP) 95-115 mmHg, with 15 days of washout, were included to the treatment initially with half tablet of the association of captopril 50 mg + hydrochlorothiazide 25 mg once daily, for 30 days. After this period, patients with DBP > 90 mmHg had the dosage duplicated, while the others had the same dosage for 60 days more. Evaluation was performed 15 days before and then every month during active drug. Results. Twenty six patients were withdrawn, 13 (2,7%) by adverse effects and 13 by protocol violation. At the end of the wash-out period, the blood pressure (BP), 162 ± 16/103 ± 6 mmHg decreased significantly at the 30th day to 146 ± 14/92 ± 8 mmHg (p < 0,001 vs 0th day); 139 ± 12/86 ± 7 mmHg at the 60th day, (p < 0,001 vs 30th day), and further to 136 ± 11/84 ± 5 mmHg (p < 0,001 vs day 0) till the end of the 90th day. Antihypertensive efficay (DBP ≤ 90 mmHg and decreased for the DBP ≥ 10 mmHg) was obtained in 82% of the patients. There was no difference in BP control considering race, hypertension level, previous antihypertensive treatment and obesity. Cough (4%) was the main adverse event. Conclusion. Captopril + hydrochlorothiazide was effective and safe in the treatment of mild to moderate hypertension. The favorable response was observed in 82% of the patients independently of race, hypertensive level, previous antihypertensive treatment and obesity. Low incidence of side effects was reported, with no difference from others reported in the literature. |
id |
UNSP_e90cdbf7d99d7c18b6d7d676723d9295 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/64629 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
EFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICOEfficacy and tolerability of the association of captopril + hydrochlorothiazide in the treatment of mild-to-moderate hypertension. A multicenter trialangiotensin converting enzyme inhibitorcaptoprilhydrochlorothiazideantihypertensive agentadultagedantihypertensive activityblood pressureclinical trialcontrolled clinical trialcontrolled studycoughingdrug efficacydrug tolerancefemalehumanhypertensionmajor clinical studymaleoral drug administrationadolescentdrug combinationdrug effectheart ratehospitalizationmiddle agedmulticenter studyAdolescentAdultAgedAged, 80 and overAntihypertensive AgentsBlood PressureCaptoprilDrug Therapy, CombinationFemaleHeart RateHumansHydrochlorothiazideHypertensionMaleMiddle AgedSeverity of Illness IndexPurpose. To evaluate the antihypertensive efficacy and tolerability of captopril 50 mg + hydrochlorothiazide 25 mg daily in mild to moderate primary hypertension. Methods. Out-patients (n = 471) with mild to moderate hypertension, diastolic blood pressure (DBP) 95-115 mmHg, with 15 days of washout, were included to the treatment initially with half tablet of the association of captopril 50 mg + hydrochlorothiazide 25 mg once daily, for 30 days. After this period, patients with DBP > 90 mmHg had the dosage duplicated, while the others had the same dosage for 60 days more. Evaluation was performed 15 days before and then every month during active drug. Results. Twenty six patients were withdrawn, 13 (2,7%) by adverse effects and 13 by protocol violation. At the end of the wash-out period, the blood pressure (BP), 162 ± 16/103 ± 6 mmHg decreased significantly at the 30th day to 146 ± 14/92 ± 8 mmHg (p < 0,001 vs 0th day); 139 ± 12/86 ± 7 mmHg at the 60th day, (p < 0,001 vs 30th day), and further to 136 ± 11/84 ± 5 mmHg (p < 0,001 vs day 0) till the end of the 90th day. Antihypertensive efficay (DBP ≤ 90 mmHg and decreased for the DBP ≥ 10 mmHg) was obtained in 82% of the patients. There was no difference in BP control considering race, hypertension level, previous antihypertensive treatment and obesity. Cough (4%) was the main adverse event. Conclusion. Captopril + hydrochlorothiazide was effective and safe in the treatment of mild to moderate hypertension. The favorable response was observed in 82% of the patients independently of race, hypertensive level, previous antihypertensive treatment and obesity. Low incidence of side effects was reported, with no difference from others reported in the literature.Dept. Clinica Medica Faculdade de Medicina UNESP, CEP 18618-000 Botucatu, SPDept. Clinica Medica Faculdade de Medicina UNESP, CEP 18618-000 Botucatu, SPUniversidade Estadual Paulista (Unesp)Velasco-Cornejo, I. F. [UNESP]Cuadrado Martin, L. [UNESP]Da Silva Franco, R. J. [UNESP]2014-05-27T11:18:01Z2014-05-27T11:18:01Z1995-08-09info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article571-575application/pdfhttp://www.arquivosonline.com.br/pesquisartigos/Pdfs/1995/V64N6/64060014.pdfArquivos Brasileiros de Cardiologia, v. 64, n. 6, p. 571-575, 1995.0066-782Xhttp://hdl.handle.net/11449/646292-s2.0-00291158892-s2.0-0029115889.pdf7095933557855151Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPporArquivos Brasileiros de Cardiologia1.318info:eu-repo/semantics/openAccess2024-08-14T17:22:27Zoai:repositorio.unesp.br:11449/64629Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T17:22:27Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
EFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICO Efficacy and tolerability of the association of captopril + hydrochlorothiazide in the treatment of mild-to-moderate hypertension. A multicenter trial |
title |
EFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICO |
spellingShingle |
EFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICO Velasco-Cornejo, I. F. [UNESP] angiotensin converting enzyme inhibitor captopril hydrochlorothiazide antihypertensive agent adult aged antihypertensive activity blood pressure clinical trial controlled clinical trial controlled study coughing drug efficacy drug tolerance female human hypertension major clinical study male oral drug administration adolescent drug combination drug effect heart rate hospitalization middle aged multicenter study Adolescent Adult Aged Aged, 80 and over Antihypertensive Agents Blood Pressure Captopril Drug Therapy, Combination Female Heart Rate Humans Hydrochlorothiazide Hypertension Male Middle Aged Severity of Illness Index |
title_short |
EFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICO |
title_full |
EFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICO |
title_fullStr |
EFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICO |
title_full_unstemmed |
EFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICO |
title_sort |
EFICACIA E TOLERABILIDADE DA ASSOCIACAO CAPTOPRIL + HIDROCLOROTIAZIDA NO TRATAMENTO DA HIPERTENSAO ARTERIAL LEVE A MODERADA. ESTUDO MULTICENTRICO |
author |
Velasco-Cornejo, I. F. [UNESP] |
author_facet |
Velasco-Cornejo, I. F. [UNESP] Cuadrado Martin, L. [UNESP] Da Silva Franco, R. J. [UNESP] |
author_role |
author |
author2 |
Cuadrado Martin, L. [UNESP] Da Silva Franco, R. J. [UNESP] |
author2_role |
author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Velasco-Cornejo, I. F. [UNESP] Cuadrado Martin, L. [UNESP] Da Silva Franco, R. J. [UNESP] |
dc.subject.por.fl_str_mv |
angiotensin converting enzyme inhibitor captopril hydrochlorothiazide antihypertensive agent adult aged antihypertensive activity blood pressure clinical trial controlled clinical trial controlled study coughing drug efficacy drug tolerance female human hypertension major clinical study male oral drug administration adolescent drug combination drug effect heart rate hospitalization middle aged multicenter study Adolescent Adult Aged Aged, 80 and over Antihypertensive Agents Blood Pressure Captopril Drug Therapy, Combination Female Heart Rate Humans Hydrochlorothiazide Hypertension Male Middle Aged Severity of Illness Index |
topic |
angiotensin converting enzyme inhibitor captopril hydrochlorothiazide antihypertensive agent adult aged antihypertensive activity blood pressure clinical trial controlled clinical trial controlled study coughing drug efficacy drug tolerance female human hypertension major clinical study male oral drug administration adolescent drug combination drug effect heart rate hospitalization middle aged multicenter study Adolescent Adult Aged Aged, 80 and over Antihypertensive Agents Blood Pressure Captopril Drug Therapy, Combination Female Heart Rate Humans Hydrochlorothiazide Hypertension Male Middle Aged Severity of Illness Index |
description |
Purpose. To evaluate the antihypertensive efficacy and tolerability of captopril 50 mg + hydrochlorothiazide 25 mg daily in mild to moderate primary hypertension. Methods. Out-patients (n = 471) with mild to moderate hypertension, diastolic blood pressure (DBP) 95-115 mmHg, with 15 days of washout, were included to the treatment initially with half tablet of the association of captopril 50 mg + hydrochlorothiazide 25 mg once daily, for 30 days. After this period, patients with DBP > 90 mmHg had the dosage duplicated, while the others had the same dosage for 60 days more. Evaluation was performed 15 days before and then every month during active drug. Results. Twenty six patients were withdrawn, 13 (2,7%) by adverse effects and 13 by protocol violation. At the end of the wash-out period, the blood pressure (BP), 162 ± 16/103 ± 6 mmHg decreased significantly at the 30th day to 146 ± 14/92 ± 8 mmHg (p < 0,001 vs 0th day); 139 ± 12/86 ± 7 mmHg at the 60th day, (p < 0,001 vs 30th day), and further to 136 ± 11/84 ± 5 mmHg (p < 0,001 vs day 0) till the end of the 90th day. Antihypertensive efficay (DBP ≤ 90 mmHg and decreased for the DBP ≥ 10 mmHg) was obtained in 82% of the patients. There was no difference in BP control considering race, hypertension level, previous antihypertensive treatment and obesity. Cough (4%) was the main adverse event. Conclusion. Captopril + hydrochlorothiazide was effective and safe in the treatment of mild to moderate hypertension. The favorable response was observed in 82% of the patients independently of race, hypertensive level, previous antihypertensive treatment and obesity. Low incidence of side effects was reported, with no difference from others reported in the literature. |
publishDate |
1995 |
dc.date.none.fl_str_mv |
1995-08-09 2014-05-27T11:18:01Z 2014-05-27T11:18:01Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://www.arquivosonline.com.br/pesquisartigos/Pdfs/1995/V64N6/64060014.pdf Arquivos Brasileiros de Cardiologia, v. 64, n. 6, p. 571-575, 1995. 0066-782X http://hdl.handle.net/11449/64629 2-s2.0-0029115889 2-s2.0-0029115889.pdf 7095933557855151 |
url |
http://www.arquivosonline.com.br/pesquisartigos/Pdfs/1995/V64N6/64060014.pdf http://hdl.handle.net/11449/64629 |
identifier_str_mv |
Arquivos Brasileiros de Cardiologia, v. 64, n. 6, p. 571-575, 1995. 0066-782X 2-s2.0-0029115889 2-s2.0-0029115889.pdf 7095933557855151 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
Arquivos Brasileiros de Cardiologia 1.318 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
571-575 application/pdf |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128123370209280 |